Tekmira Eyes mRNA Delivery as it Pushes Ahead with HBV, Other RNAi Candidates | GenomeWeb

As it eyes new opportunities for its delivery technology, Tekmira Pharmaceuticals is exploring the potential of its lipid nanoparticles (LNPs) as carriers for messenger RNA therapeutics, the company's top official said last week.

Meanwhile, as it keeps it focus primarily on its core RNAi programs, Tekmira anticipates quickly moving a hepatitis B candidate into the clinic, with data available before the end of the year, President and CEO Mark Murray said during a conference call held last week to discuss Tekmira's financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.